-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on C4 Therapeutics, Lowers Price Target to $6

Benzinga·11/06/2026 16:21:13
Listen to the news
Guggenheim analyst Michael Schmidt maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and lowers the price target from $7 to $6.